We compared the differential enrichment of miRNA in HER2+ EVs and CD24+ EVs between women with malignant and benign BI-RADS 4 lesions to previous studies that have reported differential enrichment of EV miRNA from total EV preparations in plasma EVs of women with breast cancer [45–49]. This evidence concerns the gene ERBB2 and breast cancer.